178312-62-4

Basic information

• Product Name: Homomorpholine hydrochloride
• Synonyms: HOMOMORPHOLINE HYDROCHLORIDE;HOMOMORPHOLINE HCL;Homomorpoline Hydrochloride;Homomorpholinehydrochloride,98%;Albb-008642;1,4-Oxazepine,hexahydro-, hydrochloride (1:1);[1,4]Oxazepane hydrochcloride;Hexahydro-1,4-oxazepine HCl
• CAS NO: 178312-62-4
• Molecular Formula: C5H12ClNO
• Molecular Weight: 137.61
• Mol File: 178312-62-4.mol
• Article Data: 1

Chemical Properties

• Melting Point: 156-154°C
• Boiling Point: 196.9 °C at 760 mmHg
• Flash Point: 72.9 °C
• Appearance: /
• Density: 0.909g/cm3
• Vapor Pressure: 0.328mmHg at 25°C
• Storage Temp.: Inert atmosphere,Room Temperature
• Water Solubility: Slightly soluble in water.
• Sensitive: Hygroscopic
• CAS DataBase Reference: Homomorpholine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: Homomorpholine hydrochloride(178312-62-4)
• EPA Substance Registry System: Homomorpholine hydrochloride(178312-62-4)

Safety Data

• Hazard Codes: Xi
• Statements: 10-20/21-34-65-41-37/38
• Safety Statements: 16-26-36/37/39-39
• RIDADR: 2921
• HazardClass: IRRITANT
• Hazardous Substances Data: 178312-62-4(Hazardous Substances Data)

Usage

Uses

Homomorpholine Hydrochloride is a useful synthetic intermediate. It is used to prepare homomorpholine oxazolidinone with antibacterial activities. It is also used to synthesize A2A adenosine receptor antagonists for the treatment of Parkinson's disease.

InChI:InChI=1/C5H11NO.ClH/c1-2-6-3-5-7-4-1;/h6H,1-5H2;1H

Downstream Products

• 5638-60-8 1,4-oxazepane 
• 1610737-02-4 N-((1s,4s)-4-(2-(4'-((1,4-oxazepan-4-yl)methyl)biphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexyl)-2-methylthiazole-4-carboxamide trifluoroacetic acid salt 
• 1197291-06-7 tert-butyl (1s,4s)-4-(2-(2'-((1,4-oxazepan-4-yl)methyl)-4'-hydroxybiphenyl-3-yloxy)-5-fluoronicotinamido)cyclohexylcarbamate 
• 1227065-44-2 (4-(3-(1,4-oxazepan-4-yl)pyrazin-2-yloxy)phenyl)(1H-benzo[d]imidazol-2-yl)methanone 
• 1344700-62-4 (2S)-N,2-dimethyl-2-[methyl(4-{[4-(1,4-oxazepan-4-ylmethyl)phenyl]ethynyl}benzoyl)amino]-N'-(tetrahydro-2H-pyran-2-yloxy)propanediamide 
• 1344700-27-1 ethyl 4-{[4-(1,4-oxazepan-4-ylmethyl)phenyl]ethynyl}benzoate 

Relevant articles and documents

(Azetidin-1-ylalkyl) lactams as tachykinin antagonists

The present invention provides compounds of formula (I) and the pharmaceutically acceptable salts thereof, wherein R is C3 -C7 cycloalkyl, aryl or C1 -C6 alkyl, said C1 -C6 alkyl, said C1 -C6 alkyl being optionally substituted by fluoro, COOH, --COO(C1 -C4 alkyl), C3 -C7 cycloalkyl, adamantyl, aryl or het1, and said C3 -C7 cycloalkyl being optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C3 -C7 cycloalkyl, C1 -C4 alkoxy, hydroxy, fluoro, fluoro (C1 -C4) alkyl and fluoro (C1 -C4) Alkoxy; R1 is phenyl, naphthyl, thienyl, benzothienyl or indolyl, each optionally substituted by 1 or 2 substituents each independently selected from C1 -C4 alkyl, C1 -C4 alkoxy, halo and trifluormethyl; R2 is --CO2 H, --CONR3 R4, --CONR5 (C3 -C7 cycloalkyl), --NR5 (C2 -C5 alkanoyl), --NR3 R4, --NR5 CONR5 R6, (C3 -C7 cycloalkyl-C1 -C4 alkyl)R5 N--, --NR5 COCF3, --NR5 SO2 CF3, --NR5 (SO2 C1 -C4 alkyl), --NR5 SO2 NR5 R6, --NR5 (SO2 aryl), --N(aryl) (SO2 C1 -C4 alkyl), --OR5, --O(C3 -C7 cycloalkyl), --SO2 NR5 R6, het3 or a group of formulas: (a), (b), (c), (d), (e), (f), (g) or (h); X is C1 -C4 alkylene; X1 is a direct link or C1 -C6 alkylene; X2 is a direct link, CO, SO2, or NR5 CO; and m is 0, 1 or 2; together with intermediates used in the preparation of compositions containing and the use as tachykinin angatonists of such derivatives. STR1